B of A Securities Maintains Buy on Rocket Pharmaceuticals, Raises Price Target to $9
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
B of A Securities analyst Jason Zemansky maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and raises the price target from $8 to $9.
B of A Securities analyst Jason Zemansky maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and raises the price target from $8 to $9.